News

28Feb

Atnahs Acquires Remaining Stake in Pharmanovia A/S in Denmark

Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of the remaining share capital of Pharmanovia A/S (“Pharmanovia”). Pharmanovia focuses upon developing and marketing niche pharmaceutical products and medical devices in the Nordics and beyond. Notably, it is in the process a launching Dropizol® (opium oral drops for the treatment of severe diarrhoea…

Read more

01Nov

Atnahs Launches Traxidot® (Tranexamic Acid) in the Netherlands

Basildon, UK. Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the launch of Traxidot® (Tranexamic Acid) 100mg/ml ampoules for injection (5 ampoules of 5ml) in the Netherlands. Tranexamic Acid is used for the reduction of heavy menstrual bleeding. Amit Patel, Atnahs’ Managing Director, comments, “Tranexamic Acid is the latest addition to Atnahs’ portfolio of…

Read more

01Oct

Atnahs Opens New Branch in India

Baroda, India. Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the opening of a new branch in Baroda, India. This will house Operations (mainly Regulatory) and Support (mainly Finance) staff focused in particular upon Atnahs’ New Product Development (NPD) activities. Amit Patel, Atnahs’ Managing Director, comments, “NPD is a core pillar of Atnahs’ strategy….

Read more

07Jul

Atnahs Launches Clobazam in UK, Iloprost in Portugal and Dropizol® in Denmark

Atnahs Pharma UK Limited (“Atnahs”), and its partners Pharmanovia A/S (“Pharmanovia”) and Pharmamentum ApS (“Pharmamentum”), are pleased to announce the launch of: Clobazam in the UK: Clobazam 5mg/5ml oral suspension is for the short-term relief only of anxiety that is severe or disabling, occurring alone or in association with insomnia or short term psychotic illness….

Read more

03Jul

Atnahs Acquires Rights for Bonviva® and Bondronat®

Basildon, UK. Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of worldwide rights (except for Japan and the US) for Bondronat® and Bonviva® from F. Hoffmann-La Roche Limited (“Roche”). Bonviva® and Bondronat® are injectable and tablet forms of ibandronic acid used for the treatment of osteoporosis and metastatic bone disease respectively. It…

Read more

03Jan

Atnahs Acquires Kytril®

Basildon, UK. Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of Kytril® from F.Hoffmann-La Roche Limited (“Roche”). Kytril® (granisetron hydrochloride) is an injectable and oral treatment for nausea and vomiting caused by other medical treatments, such as chemotherapy or radiotherapy. It is the third acquisition by Atnahs from Roche following Naprosyn®/ Anaprox®…

Read more